Literature DB >> 22134374

Genetic variation in CD83 and risks of cervical and vulvar cancers: a population-based case-control study.

Clara Bodelon1, Margaret M Madeleine, Lisa G Johnson, Qin Du, Mari Malkki, Effie W Petersdorf, Stephen M Schwartz.   

Abstract

OBJECTIVES: The CD83 glycoprotein is a marker of dendritic cell maturation that may contribute to the T cell response to oncogenic human papillomavirus (HPV) infection. Whether single nucleotide polymorphisms (SNPs) in CD83 influence the risk of HPV-related genital cancers has not been adequately studied. We investigated whether the common genetic variation of the CD83 region was associated with the risks of cervical and vulvar cancers in a population-based case-control study conducted in the Seattle-Puget Sound Region.
METHODS: A total of 17 tagSNPs were genotyped in the CD83 region of 886 cervical cases, 517 vulvar cases and 1100 controls. Odds ratio (OR) and 95% confidence intervals (CI) were computed to assess the risk of cervical and vulvar cancers. The interaction between the tagSNPs and cigarette smoking was also explored.
RESULTS: TagSNPs in the CD83 chromosomal region were not associated with risk of either cervical or vulvar cancer. TagSNP rs853360 was associated with a decreased risk of cervical squamous cell carcinoma (SCC) (OR=0.80; 95% CI: 0.66-0.98).
CONCLUSIONS: Our results do not suggest that the common genetic variation of CD83 is related to cervical or vulvar cancers. The association between tagSNP rs853360 and risk of cervical SCC is likely to be due to chance. If larger or pooled studies confirm our results, CD83 has little or no influence in the risk of HPV-related cancers. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22134374      PMCID: PMC3727898          DOI: 10.1016/j.ygyno.2011.11.017

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  24 in total

Review 1.  The surveillance, epidemiology, and end results program: a national resource.

Authors:  B F Hankey; L A Ries; B K Edwards
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-12       Impact factor: 4.254

2.  Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias.

Authors:  S Wacholder; N Rothman; N Caporaso
Journal:  J Natl Cancer Inst       Date:  2000-07-19       Impact factor: 13.506

Review 3.  Dendritic cells: specialized and regulated antigen processing machines.

Authors:  I Mellman; R M Steinman
Journal:  Cell       Date:  2001-08-10       Impact factor: 41.582

Review 4.  Role of CD83 in the immunomodulation of dendritic cells.

Authors:  Matthias Lechmann; Elisabeth Zinser; Antje Golka; Alexander Steinkasserer
Journal:  Int Arch Allergy Immunol       Date:  2002-10       Impact factor: 2.749

Review 5.  CD83 on dendritic cells: more than just a marker for maturation.

Authors:  Matthias Lechmann; Susanne Berchtold; Joachim Hauber; Alexander Steinkasserer
Journal:  Trends Immunol       Date:  2002-06       Impact factor: 16.687

6.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

7.  Cofactors with human papillomavirus in a population-based study of vulvar cancer.

Authors:  M M Madeleine; J R Daling; J J Carter; G C Wipf; S M Schwartz; B McKnight; R J Kurman; A M Beckmann; M E Hagensee; D A Galloway
Journal:  J Natl Cancer Inst       Date:  1997-10-15       Impact factor: 13.506

8.  Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

Authors:  Joakim Dillner; Susanne K Kjaer; Cosette M Wheeler; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine T Bryan; Roger Maansson; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Eliav Barr; Richard Haupt
Journal:  BMJ       Date:  2010-07-20

9.  The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection.

Authors:  J R Daling; M M Madeleine; B McKnight; J J Carter; G C Wipf; R Ashley; S M Schwartz; A M Beckmann; M E Hagensee; M T Mandelson; D A Galloway
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1996-07       Impact factor: 4.254

10.  Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States.

Authors:  Sean F Altekruse; James V Lacey; Louise A Brinton; Patti E Gravitt; Steven G Silverberg; Willard A Barnes; Mitchell D Greenberg; Olympia C Hadjimichael; Larry McGowan; Rodrigue Mortel; Peter E Schwartz; Allan Hildesheim
Journal:  Am J Obstet Gynecol       Date:  2003-03       Impact factor: 8.661

View more
  3 in total

1.  Association of CTLA4 gene polymorphism (rs5742909) with cervical cancer: a meta-analysis.

Authors:  Hong-Bing Xu; Huan Yang; Tingting Liu; Hong Chen
Journal:  Tumour Biol       Date:  2014-02

2.  Polymorphisms in immune mediators associate with risk of cervical cancer.

Authors:  Zhengyan Zhang; Samantha Fye; Ingrid B Borecki; Janet S Rader
Journal:  Gynecol Oncol       Date:  2014-08-12       Impact factor: 5.482

3.  Genetic variation in the TLR and NF-κB pathways and cervical and vulvar cancer risk: a population-based case-control study.

Authors:  Clara Bodelon; Margaret M Madeleine; Lisa G Johnson; Qin Du; Denise A Galloway; Mari Malkki; Effie W Petersdorf; Stephen M Schwartz
Journal:  Int J Cancer       Date:  2013-08-05       Impact factor: 7.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.